Protagonist Therapeutics, Inc. (PTGX)
Automate Your Wheel Strategy on PTGX
With Tiblio's Option Bot, you can configure your own wheel strategy including PTGX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
Published: March 20, 2026 by: Zacks Investment Research
Sentiment: Positive
PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.
Read More
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Published: March 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
Published: March 18, 2026 by: Seeking Alpha
Sentiment: Neutral
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
Read More
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
Read More
RTW Investments' Rod Wong: Expect more deals in biotech space
Published: October 10, 2025 by: CNBC Television
Sentiment: Positive
Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the sector, and much more.
Read More
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
Published: October 10, 2025 by: Reuters
Sentiment: Positive
Johnson & Johnson is in discussions to buy Protagonist Therapeutics , the Wall Street Journal reported on Friday, citing people familiar with the matter.
Read More
Johnson & Johnson in Talks to Buy Protagonist Therapeutics
Published: October 10, 2025 by: WSJ
Sentiment: Positive
The two companies are already codeveloping a treatment for ulcerative colitis.
Read More
Protagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Protagonist Therapeutics, Inc. (NASDAQ:PTGX ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Dinesh Patel - CEO, President, Secretary & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director Welcome to the second day of the Citi Biopharma Back to School Summit. I'm Geoff Meacham.
Read More
Protagonist Therapeutics: Two 'Slam Dunk' Sets Of Pivotal Data Set Up Bull Case
Published: June 20, 2025 by: Seeking Alpha
Sentiment: Positive
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & Johnson and Takeda provide significant milestone payments, royalties, and potential for $500M–$1B annual revenue by 2030, I'd speculate. A robust cash position and a promising preclinical obesity program enhance Protagonist's strategic value and acquisition appeal.
Read More
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.
Read More
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to earnings of $3.26 per share a year ago.
Read More
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Published: March 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Read More
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Published: March 10, 2025 by: Investors Business Daily
Sentiment: Positive
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily.
Read More
About Protagonist Therapeutics, Inc. (PTGX)
- IPO Date 2016-08-11
- Website https://www.protagonist-inc.com
- Industry Biotechnology
- CEO Dinesh V. Patel
- Employees 124